NVO•benzinga•
Novo Nordisk To Pay Around $2 Billion For Obesity Drug From China-Based Biotech
Summary
Novo Nordisk secures global rights (excluding China) for UBT251 in a $2B+ deal with United Biotechnology, advancing obesity and diabetes treatment.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 24, 2025 by benzinga